Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Centers for Disease Control and Prevention estimates that about 36,400 people contracted HIV in 2018.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
A recent analysis found that health care providers missed opportunities to test 90% of such patients.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
Federal judge rules in favor of nonprofit seeking to open the country’s first overdose prevention facility.
Researchers point to heroin use as a major driver of new hepatitis C and HIV cases among people who inject drugs.
Opioid use disorder is fueling a rise in youth hepatitis C cases and a stabilization of a long decline in HIV among people who use drugs.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
U.S. health care systems are seeking better solutions to the critical problem of drug diversion.
New cases of all three viruses have declined in the city over the past decade.
The city’s estimated new infection rate declined by more than 40% between 2014 and 2018.
Consistent use of medication-assisted treatment for opioid use disorder can apparently reduce this risk.
Keeping people with HIV in consistent care and on treatment for the virus is vital to ensure they benefit from an undetectable viral load.
The drug can quickly reverse opioid-driven overdoses.
Judge’s ruling may pave the way for opening the nation’s first supervised overdose prevention facility.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.